Screening Of Anti-HBS Levels And Evaluation Of Efficacy In HBV Vaccinated Medical Students. A New Version

Authors

  • Ramyaa Rajendiran, Harishmitha.A, Ravichandran. T, Hemalathaa.R, Brethis C.S

DOI:

https://doi.org/10.47750/pnr.2023.14.S01.75

Abstract

Introduction: Hepatitis is an inflammation of the liver. Hepatitis B virus infection is potentially life threatening and is a major global health problem. WHO reported around 2billion people infected with HBV and 500,000 – 700,000 people annually die of HBV related diseases .1  HBV infection deaths due to cirrhosis worldwide is around more than 235,000 cases and around 328,000 deaths due to liver cancer.2 The need of screening of anti-Hbs antibody levels in view of efficacy of anti-Hbs antibody levels following pre and post Hepatitis B vaccination and the need of booster doses especially in medical students who are at risk during clinical exposure .

Objective: 1.To assess the level of anti HBs IgG antibodies in vaccinated medical students in a tertiary care teaching hospital.

  1. To evaluate the need for boosters and the protective levels against the disease.

Method: It is a cross sectional study. Among 154 medical students, 110 medical students were included. 110 medical students who were fully vaccinated with three doses of HBV vaccine and followed up after 1-2yrs were included in the study The main exclusion criteria includes previous exposure to hepatitis B virus infection, those have not taken the complete course of vaccination and those who were not willing to participate in the study. After Institutional Ethical Committee approval a written informed consent was obtained from the subjects participating in the study. Data were collected from a structured self- administered questionnaire and analysed using SPSS version 2.1 software

Results: A total of 154,110 MBBS student across different years participated in this study. A total of 58(52.7%) male and 52 (47.3%) females participated in the study. The concentration of HBV antibody levels varies with gender. Around 10 to 100mIU/L seen in 9(52.9%) male and 8(47.1%) in female. And a concentration >100mIU/L among 43(46.2%) males and 50(53.8%) the antibody titre in the HBsAg immunized individuals.

The exposure during clinical practice showed a concentration of 10-100mIU/L in 10(58.8%) and >100mIU/L are 37(39.8%). Even when there is no clinical exposure the concentration 10-100mIU/L is 7(41.2%) and >100mIU/L is 56(60.2%).

This shows the Hbs antibody levels varies depending upon the individual immune responses and are independent of clinical exposure The duration of vaccination and concentration of HbsAb level <16 months in 10 to 100mIU/L concentration show a mean + SD of 14.8+2.6 and >16 months is 1.3+0.6 and the concentration >100mIU/L in <16 months showed mean + SD 14.4+2.4 and >16 months with >100mIU/L is 1+0.4, hence overall the immunity level are maintained throughout with significant antibody levels.

 

Downloads

Published

— Updated on 2023-01-15

Issue

Section

Articles

How to Cite

Screening Of Anti-HBS Levels And Evaluation Of Efficacy In HBV Vaccinated Medical Students. A New Version. (2023). Journal of Pharmaceutical Negative Results, 602-607. https://doi.org/10.47750/pnr.2023.14.S01.75